Head to head
ARA-290 vs KPV
Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.
Verdict
Usually stacked — and only ARA-290 has human trial data
What you are actually choosing between
Before anything else: the dataset lists ARA-290 and KPV in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.
Both are classed here as healing and repair compounds, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.
The overlap is inflammation and immune support. On this site's goal weighting — an editorial priority score, not a measure of effect size — ARA-290 rates 4/5 for inflammation and KPV rates 5/5. Outside that overlap they diverge: ARA-290 also carries weight for neuroprotection, KPV for gut health and skin and hair.
The evidence
This is the part that decides most of it. ARA-290 has controlled human trials behind it, without an approval — phase 2 results were mixed and it is approved nowhere. KPV has animal and cell data only, and no controlled human dosing trials — rodent colitis models and in-vitro work. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.
How they differ in practice
ARA-290 is a subcutaneous injection; KPV is a subcutaneous injection, taken by mouth, and applied to the skin. That is the difference most people actually feel: ARA-290 means reconstituting a vial and injecting; KPV does not require either. If needles are the deciding factor, this line settles it before any of the rest matters.
ARA-290 has a characterized half-life of 3 min; KPV does not have one published here at all. That asymmetry is worth more than it looks — it usually tracks how much formal pharmacology has been done on a compound.
Committed time differs: ARA-290 runs 4 weeks, KPV runs 8 weeks.
Risk and difficulty
KPV is rated beginner here and ARA-290 advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.
Source notes
What the evidence actually says
Verbatim, so you can check the verdict above against what it was built from.
ARA-290
Unusually well studied for this category: cibinetide reached randomized placebo-controlled phase 2 trials in sarcoidosis-associated small fiber neuropathy and in type 2 diabetes, typically 2-4 mg subcutaneously once daily for 28 days. Results were mixed and it is not approved anywhere. It is an EPO-derived peptide engineered not to stimulate erythropoiesis, so it does not raise haematocrit. Plasma half-life is only a few minutes; the effect is receptor-mediated and outlasts the exposure.
KPV
The anti-inflammatory tripeptide tail of alpha-MSH. Evidence is animal and cell-culture only, mainly rodent colitis models and in-vitro work on NF-kB signaling. There are no controlled human dosing trials, so the 200-500 mcg daily figures are compounding-pharmacy and community convention, not trial data.
Side by side
The numbers
| Attribute | ARA-290 | KPV |
|---|---|---|
| Class | Healing & repair | Healing & repair |
| Routes | Subcutaneous | Subcutaneous, Oral, Topical |
| Dose range | 2 mg–4 mg (typical 4 mg) | 200 mcg–500 mcg (typical 500 mcg) |
| Frequency | Once daily | Once daily |
| Half-life | 3 min | Not characterized |
| Cycle length | 4 weeks | 8 weeks |
| Experience | Advanced | Beginner |
| Evidence | Controlled human trials | Animal / cell data only |
| Contraindications |
|
|
| Side effects |
|
|
Goals
Where they overlap, and where they do not
| Goal | ARA-290 | KPV |
|---|---|---|
| inflammation | ARA-290: 4/5 | KPV: 5/5 |
| immune support | ARA-290: 3/5 | KPV: 4/5 |
| injury repair | ARA-290: 2/5 | KPV: 2/5 |
| gut healthone only | ARA-290: — | KPV: 5/5 |
| neuroprotectionone only | ARA-290: 5/5 | KPV: — |
| skin and hairone only | ARA-290: — | KPV: 3/5 |
| metabolic healthone only | ARA-290: 2/5 | KPV: — |
They overlap on 3 goals and diverge on 4. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.
Next
Go deeper
Related
Other comparisons with these two
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.